Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus chemotherapy vs trastuzumab plus chemotherapy in first-line HER2-positive metastatic breast cancer
2010-019390-15Phase 2Terminated
- Sponsor
- GSK
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Lapatinib plus chemotherapy with Trastuzumab plus chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Sep 2010; status: terminated.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-019390-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019390-15.